<DOC>
	<DOCNO>NCT01760447</DOCNO>
	<brief_summary>The purpose study assess safety efficacy addition sitagliptin ( administer MK-0431A XR ) compare addition placebo therapy extended-release metformin ( metformin XR ) treatment type 2 diabetes mellitus ( T2DM ) pediatric participant inadequate glycemic control metformin therapy ( alone combination insulin ) . The primary hypothesis addition sitagliptin reduces hemoglobin A1c ( A1C ) addition placebo 20 week treatment .</brief_summary>
	<brief_title>A Study Safety Efficacy MK-0431A XR Pediatric Participants With Type 2 Diabetes Mellitus ( MK-0431A-289 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Has T2DM A1C great equal 6.5 % less equal 10.0 % metformin ( great equal 1500 mg/day ) without insulin great equal 12 week OR A1C great equal 7 % less equal 10.0 % metformin ( great equal 1500 mg/day ) insulin great equal 12 week . NOTE : Participants daily dose metformin great equal 1000 mg/day , less 1500 mg/day great equal 12 week may eligible documentation high dos tolerate . Between 10 17 year age ( inclusive ) Male , female unlikely conceive ( nonsterilized , sexually active agrees abstain heterosexual activity agree use adequate method contraception ) study 14 day last dose study drug Has type 1 diabetes mellitus Has monogenic diabetes secondary diabetes Has previously take dipeptidyl peptidase IV ( DPP4 ) inhibitor ( sitagliptin , vildagliptin , alogliptin , saxagliptin , linagliptin ) glucagonlike peptide1 ( GLP1 ) receptor agonist ( exenatide liraglutide ) Is likely require treatment &gt; =2 consecutive week repeat course corticosteroid ( inhale , nasal topical corticosteroid permit ) Has undergone surgical procedure within 4 week study participation plan major surgery study History congenital heart disease cardiovascular disease hypertension History active liver disease ( nonalcoholic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Active neuropathy ( nephrotic syndrome glomerulonephritis ) Chronic myopathy , mitochondrial disorder progressive neurological neuromuscular disorder Human immunodeficiency virus ( HIV ) Hematological disorder ( aplastic anemia , thrombocytopenia , myeloproliferative myelodysplastic syndrome ) Is currently treat hyperthyroidism thyroid hormone therapy stable dose least 6 week History malignancy &lt; =5 year prior study participation , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer History idiopathic acute pancreatitis chronic pancreatitis History recreational illicit drug use , alcohol abuse dependence ( within past year ) Has donate blood product phlebotomy &gt; 10 % estimate total blood volume within 8 week study participation , intend donate blood product receive blood product within project duration study Is pregnant breastfeeding , expect conceive donate egg study , include 14 day follow last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>